These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 11474010)

  • 1. Serosubtypes and PorA types of Neisseria meningitidis serogroup B isolated in Brazil during 1997--1998: overview and implications for vaccine development.
    Sacchi CT; Lemos AP; Popovic T; De Morais JC; Whitney AM; Melles CE; Brondi LM; Monteiro LM; Paiva MV; Solari CA; Mayer LW
    J Clin Microbiol; 2001 Aug; 39(8):2897-903. PubMed ID: 11474010
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diversity and prevalence of PorA types in Neisseria meningitidis serogroup B in the United States, 1992-1998.
    Sacchi CT; Whitney AM; Popovic T; Beall DS; Reeves MW; Plikaytis BD; Rosenstein NE; Perkins BA; Tondella ML; Mayer LW
    J Infect Dis; 2000 Oct; 182(4):1169-76. PubMed ID: 10979914
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distribution of Neisseria meningitidis serogroup B serosubtypes and serotypes circulating in the United States. The Active Bacterial Core Surveillance Team.
    Tondella ML; Popovic T; Rosenstein NE; Lake DB; Carlone GM; Mayer LW; Perkins BA
    J Clin Microbiol; 2000 Sep; 38(9):3323-8. PubMed ID: 10970378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of sequence variation in meningococcal PorA outer membrane protein on the effectiveness of a hexavalent PorA outer membrane vesicle vaccine.
    Martin SL; Borrow R; van der Ley P; Dawson M; Fox AJ; Cartwright KA
    Vaccine; 2000 May; 18(23):2476-81. PubMed ID: 10775781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidemiology of pathogenic Neisseria meningitidis serogroup B serosubtypes in Malta: implications for introducing PorA based vaccines.
    Pace D; Cuschieri P; Galea Debono A; Attard-Montalto S
    Vaccine; 2008 Nov; 26(47):5952-6. PubMed ID: 18801401
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High prevalence of Neisseria meningitidis hypervirulent lineages and emergence of W135:P1.5,2:ST-11 clone in Southern Brazil.
    Weidlich L; Baethgen LF; Mayer LW; Moraes C; Klein CC; Nunes LS; Rios Sda S; Kmetzsch CI; Rossetti ML; Zaha A
    J Infect; 2008 Oct; 57(4):324-31. PubMed ID: 18814914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neisseria meningitidis PorA variable regions: rapid detection of P1.7 and P1.19 variants by PCR.
    de Filippis I; de Andrade CF; de Almeida AE; Clementino MM; Fernandes CA; de Carvalho ML; Vicente AC
    Lett Appl Microbiol; 2007 Oct; 45(4):426-31. PubMed ID: 17897387
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PorA types in Neisseria meningitidis serogroup B isolated in Argentina from 2001 to 2003: implications for the design of an outer membrane protein-based vaccine.
    Sorhouet Pereira C; Regueira M; Mollerach M
    J Med Microbiol; 2008 Mar; 57(Pt 3):338-342. PubMed ID: 18287297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antigenic diversity of Neisseria meningitidis isolated in Taiwan between 1995 and 2002.
    Yang CY; Lee YS; Huang LS; Kuo YL; Liu YL; Lu CH
    Scand J Infect Dis; 2006; 38(4):273-80. PubMed ID: 16709528
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stability of PorA during a meningococcal disease epidemic.
    Devoy AF; Dyet KH; Martin DR
    J Clin Microbiol; 2005 Feb; 43(2):832-7. PubMed ID: 15695688
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Analysis of molecular subtypes and microflora structure of Neisseria meningitidis strains isolated in Jiangxi province].
    Yang M; Zhou HJ; Yuan H; Xiong CH; Xu XQ; Chen FH
    Zhonghua Yu Fang Yi Xue Za Zhi; 2013 Apr; 47(4):342-6. PubMed ID: 23928641
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multivalent liposome-based vaccines containing different serosubtypes of PorA protein induce cross-protective bactericidal immune responses against Neisseria meningitidis.
    Humphries HE; Williams JN; Blackstone R; Jolley KA; Yuen HM; Christodoulides M; Heckels JE
    Vaccine; 2006 Jan; 24(1):36-44. PubMed ID: 16105711
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The VR2 epitope on the PorA P1.7-2,4 protein is the major target for the immune response elicited by the strain-specific group B meningococcal vaccine MeNZB.
    Martin DR; Ruijne N; McCallum L; O'Hallahan J; Oster P
    Clin Vaccine Immunol; 2006 Apr; 13(4):486-91. PubMed ID: 16603616
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of invasive Neisseria meningitidis strains from Québec, Canada, during a period of increased serogroup B disease, 2009-2013: phenotyping and genotyping with special emphasis on the non-carbohydrate protein vaccine targets.
    Law DK; Lefebvre B; Gilca R; Deng S; Zhou J; De Wals P; Tsang RS
    BMC Microbiol; 2015 Jul; 15():143. PubMed ID: 26204985
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Specificity of bactericidal antibody response to serogroup B meningococcal strains in Brazilian children after immunization with an outer membrane vaccine.
    Milagres LG; Gorla MC; Sacchi CT; Rodrigues MM
    Infect Immun; 1998 Oct; 66(10):4755-61. PubMed ID: 9746575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic Similarity of Gonococcal Homologs to Meningococcal Outer Membrane Proteins of Serogroup B Vaccine.
    Marjuki H; Topaz N; Joseph SJ; Gernert KM; Kersh EN; ; Wang X
    mBio; 2019 Sep; 10(5):. PubMed ID: 31506309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phenotypic assessment of Neisseria meningitidis isolates obtained from patients with invasive meningococcal disease in Greece, 1993-2003: implications for serogroup B vaccines based on PorA serosubtype antigens.
    Tzankaki G; Markou F; Kesanopoulos K; Levidiotou S; Pangalis A; Tsolia M; Liakou V; Papapavasiliou E; Voyiatzi A; Kansouzidou A; Foustoukou M; Blackwell C; Kremastinou J
    Vaccine; 2006 Feb; 24(6):819-25. PubMed ID: 16153759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Meningococcal vaccine development--from glycoconjugates against MenACWY to proteins against MenB--potential for broad protection against meningococcal disease.
    Dull PM; McIntosh ED
    Vaccine; 2012 May; 30 Suppl 2():B18-25. PubMed ID: 22607895
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of fHbp, nhba (gna2132), nadA, porA, and sequence type in group B meningococcal case isolates collected in England and Wales during January 2008 and potential coverage of an investigational group B meningococcal vaccine.
    Lucidarme J; Comanducci M; Findlow J; Gray SJ; Kaczmarski EB; Guiver M; Vallely PJ; Oster P; Pizza M; Bambini S; Muzzi A; Borrow R
    Clin Vaccine Immunol; 2010 Jun; 17(6):919-29. PubMed ID: 20375242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Murine monoclonal antibodies to PorA of Neisseria meningitidis show reduced protective activity in vivo against B:15:P1.7,16 subtype variants in an infant rat infection model.
    Toropainen M; Saarinen L; van der Ley P; Kuipers B; Käyhty H
    Microb Pathog; 2001 Mar; 30(3):139-48. PubMed ID: 11273739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.